A Study to Evaluate the Safety and Efficacy of YM150 in Patients With Knee Replacement Surgery
NCT ID: NCT00595426
Last Updated: 2013-03-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
685 participants
INTERVENTIONAL
2008-05-31
2009-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Knee Replacement Surgery
NCT00917254
Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Hip Replacement Surgery
NCT00913120
A Study Evaluating Efficacy and Safety of YM150 Compared to Enoxaparin in Subjects Undergoing Hip Replacement Surgery
NCT00902928
Factor Xa Inhibitor for Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Knee Replacement
NCT00408239
Prevention of Venous Thromboembolism in Subjects Undergoing Hip Fracture Surgery or Surgery in the Lower Extremities
NCT00937911
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1. YM150 Dose X, twice daily
YM150
Oral
2. YM150 Dose Y, once daily
YM150
Oral
3. YM150 Dose Y, twice daily
YM150
Oral
4. YM150 Dose Z, once daily
YM150
Oral
5. Warfarin
various doses
Warfarin
Oral
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
YM150
Oral
Warfarin
Oral
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Written Informed consent obtained
Exclusion Criteria
* Subject is considered to be at increased risk of VTE
* Subject has active bleeding or any condition associated with increased risk of bleeding
* Subject is planning to have surgery on the contralateral knee at the same time or within 6 weeks after enrollment into the study
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Astellas Pharma Inc
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Central Contact
Role: STUDY_DIRECTOR
Astellas Pharma Global Development
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Mobile, Alabama, United States
Phoenix, Arizona, United States
Tuscon, Arizona, United States
Little Rock, Arkansas, United States
Fountain Valley, California, United States
La Mesa, California, United States
Long Beach, California, United States
Long Beach, California, United States
San Diego, California, United States
Santa Ana, California, United States
Torrance, California, United States
Yuba City, California, United States
Aurora, Colorado, United States
Denver, Colorado, United States
Lone Tree, Colorado, United States
Washington D.C., District of Columbia, United States
Bay Pines, Florida, United States
Bradenton, Florida, United States
Gulf Breeze, Florida, United States
Hollywood, Florida, United States
St. Petersburg, Florida, United States
St. Petersburg, Florida, United States
Decatur, Georgia, United States
Savannah, Georgia, United States
Boise, Idaho, United States
Idaho Falls, Idaho, United States
Springfield, Illinois, United States
Springfield, Illinois, United States
Baltimore, Maryland, United States
Cincinnati, Ohio, United States
Cleveland, Ohio, United States
Tulsa, Oklahoma, United States
Charleston, South Carolina, United States
Austin, Texas, United States
Dallas, Texas, United States
Grapevine, Texas, United States
Houston, Texas, United States
Lubbock, Texas, United States
Lubbock, Texas, United States
Odessa, Texas, United States
San Antonio, Texas, United States
San Antonio, Texas, United States
Richmond, Virginia, United States
Richmond, Virginia, United States
Red Deer, Alberta, Canada
Ajax, Ontario, Canada
Burlington, Ontario, Canada
Montreal, Ontario, Canada
Newmarket, Ontario, Canada
Saint Catherines, Ontario, Canada
Scarborough Village, Ontario, Canada
Thunder Bay, Ontario, Canada
Waterloo, Ontario, Canada
Charlottetown, Prince Edward Island, Canada
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
150-CL-033
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.